What Is IBS Really? Why It Is a Description Not a Diagnosis and What That Means for You

If you’ve been told you have irritable bowel syndrome (IBS), you may have left the doctor’s office feeling relieved to finally have a name for your symptoms — but also frustrated that you weren’t given any real explanation of why your gut is behaving this way, or what to actually do about it.

Here’s something most patients are never told: IBS is not a diagnosis in the traditional sense. It is a description of symptoms. It tells you what is happening — but not why. And that distinction matters enormously, because finding the underlying cause is precisely what makes lasting recovery possible.

In over a decade of clinical practice, the most transformative shift I see in my clients is when they move from thinking “I have IBS” to asking “what is causing my IBS?” That question opens the door to real answers — and real solutions.

This guide is designed to give you exactly that.

What Is IBS? The Official Definition (And Its Limits)

IBS is currently classified as a disorder of gut-brain interaction — a term introduced in the most recent edition of the Rome IV diagnostic criteria (2016), which replaced the older label of “functional bowel disorder.” The change was significant: it acknowledged that IBS involves a genuine physiological disruption in the communication between the gut and the brain, not simply a psychological or stress-related condition.

To receive a formal IBS diagnosis under Rome IV criteria, you must have:

• Recurrent abdominal pain, on average at least one day per week over the past three months
• That pain must be associated with two or more of the following: a change in stool frequency, a change in stool appearance, or relief (or worsening) with defecation

Based on stool consistency, IBS is then classified into subtypes:

• IBS-D — diarrhoea-predominant
• IBS-C — constipation-predominant
• IBS-M — mixed bowel habits
• IBS-U — unclassified

These subtypes aren’t just clinical labels — research shows they have meaningfully different gut microbiome profiles, different underlying mechanisms, and different responses to treatment. I’ll come back to this in a moment.

The critical limitation of this approach is that the Rome IV criteria say nothing about cause. They are a checklist of symptoms, used largely to rule out more serious pathology like inflammatory bowel disease (IBD) or coeliac disease. Once those are excluded, IBS is what remains. The label is, in essence, a diagnosis of exclusion — a description of what your gut is doing, with no information about why.

Why Symptoms Alone Are Not Enough: The Case for Going Deeper

Consider an analogy. If someone goes to their GP complaining of a persistent cough, the doctor wouldn’t simply say “you have a coughing disorder” and send them home. They’d ask: is it an infection? Allergies? Acid reflux? A structural issue? The cough is a symptom. The cause is what needs treating.

IBS works the same way. The bloating, the cramping, the unpredictable bowel habits — these are symptoms. They can arise from a range of very different underlying problems. Treating the symptoms without addressing the root cause is why so many people with IBS cycle through low-FODMAP diets, antispasmodics, and peppermint oil for years with only partial relief.

A functional medicine approach asks the question the Rome criteria don’t: what is driving these symptoms in this individual person?

Research increasingly supports this view. A landmark study published in Gut Microbes (Su et al., 2023), analysing data from 942 carefully matched IBS patients, found that each IBS subtype has a distinct gut microbiome signature — meaning different patients have different microbial imbalances, different functional pathway disruptions, and likely different underlying causes. The study identified 101 subtype-specific bacterial signatures, demonstrating clearly that IBS is not one condition but a cluster of related conditions sharing a common symptom pattern.

The Major Underlying Causes of IBS

1. Small Intestinal Bacterial Overgrowth (SIBO)

One of the most significant paradigm shifts in gut health over the past two decades has been the recognition that a substantial proportion of IBS cases are driven by small intestinal bacterial overgrowth (SIBO) — an abnormal proliferation of bacteria in the small intestine, where bacterial counts should normally be low.

Research published in Gut and Liver (Ghoshal et al., 2017) found that between 4% and 78% of IBS patients test positive for SIBO, depending on the diagnostic method used, compared to just 1–5% of healthy controls. Two separate meta-analyses confirmed the association, with patients with IBS being approximately 3.5 to 4.7 times more likely to have SIBO than controls.

SIBO drives IBS symptoms through several mechanisms:

• Bacterial fermentation of dietary carbohydrates in the small intestine, producing hydrogen and methane gas — causing bloating, distension, flatulence, and pain
• Methane gas specifically is known to slow gut transit, contributing to constipation
• Deconjugation of bile salts, contributing to diarrhoea
• Increased intestinal permeability (“leaky gut”), driving low-grade immune activation and inflammation
• Disruption of carbohydrate digestion, including secondary lactase deficiency

Notably, SIBO is more common in those with IBS-D and is associated with marked bloating and flatulence, female sex, older age, and the use of proton pump inhibitors (PPIs) or opioid medications.

SIBO can be hydrogen-producing, methane-producing (now reclassified as Intestinal Methanogen Overgrowth, or IMO), or involve hydrogen sulphide — and each type has different clinical patterns. Accurate testing is therefore essential to guide treatment.

Think you have SIBO/IMO?

Shop our gut health tests

2. Gut Microbiome Dysbiosis

Even in the absence of true SIBO, dysbiosis — a disruption in the composition, diversity, and function of the gut microbiome — is now one of the most replicated findings in IBS research.

The Su et al. (2023) study found that across all IBS subtypes, certain bacteria were consistently depleted, including Sutterella, Faecalibacterium, and Bifidobacterium — all important short-chain fatty acid (SCFA) producers and anti-inflammatory bacteria. Meanwhile, potentially pathogenic organisms including Escherichia/Shigella were elevated in all subtypes.

The functional consequences are significant. Depleted SCFA production means reduced butyrate — the primary fuel for colonocytes, and a key regulator of gut barrier integrity and immune tone. Reduced Bifidobacterium is specifically linked to lower SCFA production and, intriguingly, also to depression comorbidity in IBS patients.

IBS subtypes also show distinct dysbiosis patterns:

• IBS-D is associated with increased hydrogen sulphide production (via the SO4ASSIM pathway), elevated Ruminococcus gnavus (a pro-inflammatory species), and reduced Akkermansia and Alistipes
• IBS-C shows increased Akkermansia and Desulfobacterota, along with elevated palmitoleate biosynthesis — a pathway whose end product, palmitic acid, binds calcium to form calcium palmitate, which correlates with harder stools
• IBS-U shows reduced butyrate production and increased hydrogen sulphide, with depleted Turicibacter

These are not subtle differences. They point to genuinely distinct biological processes operating in different individuals — which is why one-size-fits-all approaches to IBS so often fall short.

Want answers?

Shop our gut health tests

3. Post-Infectious IBS (PI-IBS)

Have you noticed your digestive symptoms began — or significantly worsened — after a bout of food poisoning, gastroenteritis, or traveller’s diarrhoea? If so, you may have post-infectious IBS.

Research consistently shows that around 10% of people who experience acute gastroenteritis go on to develop IBS, even after the original infection has fully resolved. The pathogens most strongly associated with PI-IBS include Campylobacter, Salmonella, Shigella, E. coli, Norovirus, Rotavirus, and Giardia.

The mechanisms are now becoming clearer. Exposure to a pathogen triggers a shift in gut microbiota composition, with disruptions in host-microbiome interactions that can persist for months or years. This affects gut-brain axis signalling, increases visceral sensitivity, disrupts the intestinal mucosal barrier, and sustains low-grade immune activation — all of which can maintain IBS symptoms long after the infection itself is gone.

A 2025 umbrella review of 69 systematic reviews (Sulaimi et al., BMC Medicine) confirmed that gastroenteritis is one of the most robustly evidenced risk factors for IBS, with an association magnitude of 3.8-fold increased risk (relative risk) and odds ratios of 5.86–7.3.

4. Intestinal Permeability and Immune Activation

A recurrent theme across IBS subtypes is increased intestinal permeability — sometimes called “leaky gut.” When the tight junctions between intestinal epithelial cells become compromised, bacterial products (including lipopolysaccharide from gram-negative bacteria) can translocate across the gut wall, triggering immune responses that drive visceral hypersensitivity, motility disruption, and systemic inflammation.

This is not theoretical. Increased intestinal permeability has been formally identified as a physiological risk factor for IBS in multiple systematic reviews. SIBO itself worsens permeability by producing toxic compounds including peptidoglycans and D-lactate that damage the enterocyte brush border. This creates a self-reinforcing cycle: dysbiosis drives permeability, and permeability drives further immune activation.

5. The Gut-Brain Axis and Psychological Factors

It would be incomplete to discuss IBS without acknowledging the gut-brain axis — but it’s equally important to frame it correctly.

The fact that anxiety, depression, and stress are risk factors for IBS does not mean IBS is “in your head.” It means the gut and brain are in constant bidirectional communication, via the vagus nerve, the enteric nervous system, immune signalling, and the microbiome itself. Psychological stress activates the hypothalamic-pituitary-adrenal (HPA) axis, increasing corticotropin-releasing hormone (CRH), which alters gut motility, increases visceral sensitivity, and can drive stress-induced microbiome dysbiosis.

The Sulaimi et al. (2025) umbrella review rated depression as a moderate-evidence risk factor for IBS, with associations of 1.49–2.15-fold increased odds. Notably, the Su et al. (2023) microbiome study found that IBS patients with comorbid depression had significantly lower levels of Bifidobacterium, Sutterella, and Butyricimonas, and markedly depleted SCFA production pathways — suggesting the gut-brain connection operates in part through the microbiome.

This means that gut-targeted interventions can support both digestive and mental health outcomes in IBS.

6. Dietary Factors

Diet is both a driver of and a solution to IBS — but what works varies considerably between subtypes.

The Su et al. (2023) study found that lactose consumption was associated with greater microbiome divergence from healthy controls across all subtypes, while red wine consumption appeared to narrow that gap. Fruit consumption was protective in IBS-D; dairy and wholegrains appeared beneficial in IBS-U and IBS-C.

The ultra-processed food connection is also well established — high UPF consumption is an independently documented risk factor for IBS development. Alcohol and fatty foods are similarly implicated.

The low-FODMAP diet remains the most evidence-based dietary intervention for IBS symptom reduction. However, it works by reducing substrate for bacterial fermentation — meaning it is, in effect, managing a microbial problem rather than resolving it. For many people, identifying and correcting the underlying dysbiosis allows for a broader, more sustainable dietary freedom over time.

7. Other Contributing Factors Worth Knowing About

The umbrella review by Sulaimi et al. (2025) identified several additional risk factors supported across multiple systematic reviews:

• Female sex — women are approximately 1.4 to 2.3 times more likely to develop IBS, likely related to hormonal influences on gut motility, the serotonin system, and visceral sensitivity
• Early life adversity — childhood trauma, abuse, adverse parenting environments, and low birth weight are all associated with IBS development, likely through lasting effects on HPA axis reactivity and gut-brain signalling
• Antibiotic exposure — repeated antibiotic use disrupts microbiome composition and is a documented risk factor for IBS
• Vitamin D deficiency
• Endometriosis (in women)
• Helicobacter pylori infection
• Blastocystis and Dientamoeba fragilis — two intestinal parasites that are more common in IBS patients than in healthy controls

The Subtype Question: Why It Matters More Than You Think

One of the most clinically important findings to emerge from recent microbiome research is that analysing IBS without accounting for subtype can actively mislead you.

The Su et al. (2023) study demonstrated this elegantly. When IBS patients of all subtypes were pooled together, the microbiome differences versus controls were relatively modest, and many subtype-specific signals cancelled each other out. For example, Akkermansia — a key gut health bacterium — was decreased in IBS-D but increased in IBS-C. Treating all IBS the same and targeting Akkermansia as a blanket intervention would help some and potentially worsen others.

When subtypes were analysed separately, 101 distinct bacterial signatures emerged. This has direct clinical implications: the right investigation tells you the right thing to treat.

So What Should You Do? A Functional Medicine Approach to IBS

Rather than managing symptoms indefinitely, a functional medicine approach to IBS involves:

1. Accurate subtype identification — knowing whether you have IBS-D, IBS-C, or IBS-U matters, because the underlying biology differs
2. Testing for SIBO or IMO — particularly if you have significant bloating, gas, altered stool consistency, or symptoms that began after a gut infection or antibiotic course
3. Comprehensive gut microbiome assessment — to identify dysbiosis, pathogenic overgrowths, depleted beneficial species, reduced diversity, and functional markers including SCFA production
4. Investigating for relevant pathogens — including H. pylori, Blastocystis, Dientamoeba fragilis, (included in our Ultimate Gut Health test) and others depending on clinical history.
5. Nutritional and lifestyle support — targeted to your specific microbiome findings and subtype, not a generic protocol
6. Addressing the gut-brain axis — where psychological factors are present, integrating gut-directed psychotherapy, nervous system regulation, and stress resilience support

The goal is not just symptom relief. It is to understand and correct the underlying biology so that over time you can live without your gut dictating the terms of your life.

Key Takeaways

• IBS is a symptom-based description, not a mechanistic diagnosis — it tells you what, not why
• The Rome IV criteria are a useful clinical tool for symptom classification, but they do not identify underlying causes
• Major drivers of IBS include SIBO, gut microbiome dysbiosis, post-infectious changes, intestinal permeability, the gut-brain axis, and dietary factors
• Different IBS subtypes have distinct microbiome profiles and biological mechanisms — this is why personalised investigation matters
• Testing for SIBO and comprehensively assessing the gut microbiome are the most direct ways to identify what is actually causing your symptoms
• Correcting the root cause — rather than managing symptoms indefinitely — is both possible and achievable

References

Su Q, Tun HM, Liu Q, et al. Gut microbiome signatures reflect different subtypes of irritable bowel syndrome. Gut Microbes. 2023;15(1):2157697.

Ghoshal UC, Shukla R, Ghoshal U. Small intestinal bacterial overgrowth and irritable bowel syndrome: a bridge between functional organic dichotomy. Gut Liver. 2017;11(2):196–208.

Sulaimi F, Ong TSK, Tang ASP, et al. Risk factors for developing irritable bowel syndrome: systematic umbrella review of reviews. BMC Medicine. 2025;23:103.

Lupu VV, Ghiciuc CM, Stefanescu G, et al. Emerging role of the gut microbiome in post-infectious irritable bowel syndrome: a literature review. World J Gastroenterol. 2023;29(21):3241–3256.